Page last updated: 2024-10-27

gliclazide and Peripheral Arterial Disease

gliclazide has been researched along with Peripheral Arterial Disease in 1 studies

Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.

Peripheral Arterial Disease: Lack of perfusion in the EXTREMITIES resulting from atherosclerosis. It is characterized by INTERMITTENT CLAUDICATION, and an ANKLE BRACHIAL INDEX of 0.9 or less.

Research Excerpts

ExcerptRelevanceReference
"We analyzed 10,624 patients with type 2 diabetes free from baseline major PAD in the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) clinical trial."2.82Microvascular and Macrovascular Disease and Risk for Major Peripheral Arterial Disease in Patients With Type 2 Diabetes. ( Chalmers, J; Harrap, S; Hirakawa, Y; Lisheng, L; Mancia, G; Marre, M; Mohammedi, K; Neal, B; Rodgers, A; Williams, B; Woodward, M; Zoungas, S, 2016)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Mohammedi, K1
Woodward, M1
Hirakawa, Y1
Zoungas, S1
Williams, B1
Lisheng, L1
Rodgers, A1
Mancia, G1
Neal, B1
Harrap, S1
Marre, M1
Chalmers, J1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron - MR Controlled Evaluation[NCT00145925]Phase 311,140 participants (Actual)Interventional2001-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

1 trial available for gliclazide and Peripheral Arterial Disease

ArticleYear
Microvascular and Macrovascular Disease and Risk for Major Peripheral Arterial Disease in Patients With Type 2 Diabetes.
    Diabetes care, 2016, Volume: 39, Issue:10

    Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations; Endpoint Determination; Female; F

2016